Altimmune Inc. $(ALT)$ shares _老虎社区_美港股上老虎

2021-06-30

Altimmune Inc. $(ALT)$ shares dropped in the extended session Tuesday after the biotech said it was discontinuing study of a COVID-19 nasal spray vaccine because it didn't work as well as anticipated.

Altimmune stock falls after it drops development of nasal COVID-19 vaccine

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":153369652,"tweetId":"153369652","gmtCreate":1625010470676,"gmtModify":1631889012669,"author":{"id":3583568085402852,"idStr":"3583568085402852","authorId":3583568085402852,"authorIdStr":"3583568085402852","name":"IsaacYap90","avatar":"https://static.tigerbbs.com/40f66d0266826bb209ee22688d7bbde5","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":51,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Altimmune Inc. $(ALT)$ shares dropped in the extended session Tuesday after the biotech said it was discontinuing study of a COVID-19 nasal spray vaccine because it didn't work as well as anticipated.&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Altimmune Inc. $(ALT)$ shares dropped in the extended session Tuesday after the biotech said it was discontinuing study of a COVID-19 nasal spray vaccine because it didn't work as well as anticipated.&nbsp;</p></body></html>","text":"Altimmune Inc. $(ALT)$ shares dropped in the extended session Tuesday after the biotech said it was discontinuing study of a COVID-19 nasal spray vaccine because it didn't work as well as anticipated.","highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/153369652","repostId":2147603368,"repostType":4,"repost":{"id":"2147603368","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1625009040,"share":"https://www.laohu8.com/m/news/2147603368?lang=&edition=full","pubTime":"2021-06-30 07:24","market":"us","language":"en","title":"Altimmune stock falls after it drops development of nasal COVID-19 vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2147603368","media":"Dow Jones","summary":"MW Altimmune stock falls after it drops development of nasal COVID-19 vaccine\nAltimmune Inc. $(ALT)$","content":"<p>MW Altimmune stock falls after it drops development of nasal COVID-19 vaccine</p>\n<p>Altimmune Inc. <a href=\"https://laohu8.com/S/ALT\">$(ALT)$</a> shares dropped in the extended session Tuesday after the biotech said it was discontinuing study of a COVID-19 nasal spray vaccine because it didn't work as well as anticipated. Altimmune shares fell 33% after hours, following a 2.5% decline to close at $15.90. The company called study results of its AdCOVID vaccine \"disappointing\" and said it would focus on its treatments for obesity and liver disease. \"Although antibodies were detected that bound the SARS-CoV-2 Spike protein and neutralized the virus in a subset of subjects, the magnitude of the response and the percent of subjects responding to AdCOVID were substantially lower than what had been demonstrated for other vaccines already authorized for emergency use,\" Altimmune said in a statement. Shares had gained 53% over the past 12 months, compared with a 41% gain on the S&amp;P 500 index .</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Altimmune stock falls after it drops development of nasal COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAltimmune stock falls after it drops development of nasal COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-30 07:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>MW Altimmune stock falls after it drops development of nasal COVID-19 vaccine</p>\n<p>Altimmune Inc. <a href=\"https://laohu8.com/S/ALT\">$(ALT)$</a> shares dropped in the extended session Tuesday after the biotech said it was discontinuing study of a COVID-19 nasal spray vaccine because it didn't work as well as anticipated. Altimmune shares fell 33% after hours, following a 2.5% decline to close at $15.90. The company called study results of its AdCOVID vaccine \"disappointing\" and said it would focus on its treatments for obesity and liver disease. \"Although antibodies were detected that bound the SARS-CoV-2 Spike protein and neutralized the virus in a subset of subjects, the magnitude of the response and the percent of subjects responding to AdCOVID were substantially lower than what had been demonstrated for other vaccines already authorized for emergency use,\" Altimmune said in a statement. Shares had gained 53% over the past 12 months, compared with a 41% gain on the S&amp;P 500 index .</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147603368","content_text":"MW Altimmune stock falls after it drops development of nasal COVID-19 vaccine\nAltimmune Inc. $(ALT)$ shares dropped in the extended session Tuesday after the biotech said it was discontinuing study of a COVID-19 nasal spray vaccine because it didn't work as well as anticipated. Altimmune shares fell 33% after hours, following a 2.5% decline to close at $15.90. The company called study results of its AdCOVID vaccine \"disappointing\" and said it would focus on its treatments for obesity and liver disease. \"Although antibodies were detected that bound the SARS-CoV-2 Spike protein and neutralized the virus in a subset of subjects, the magnitude of the response and the percent of subjects responding to AdCOVID were substantially lower than what had been demonstrated for other vaccines already authorized for emergency use,\" Altimmune said in a statement. Shares had gained 53% over the past 12 months, compared with a 41% gain on the S&P 500 index .","news_type":1},"isVote":1,"tweetType":1,"viewCount":1355,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["ALT"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":169,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/153369652"}